SCV-07 (SciClone Pharmaceuticals/Verta)

Curr Opin Investig Drugs. 2006 Feb;7(2):180-5.

Abstract

SciClone Pharmaceuticals and Verta are developing SCV-07, the lead in a series of immnunostimulants from Verta, for the potential treatment of tuberculosis and hepatitis C virus infection. Phase II clinical trials of the compound are ongoing.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacokinetics
  • Adjuvants, Immunologic / therapeutic use*
  • Animals
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use*
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / pharmacokinetics
  • Antiviral Agents / therapeutic use*
  • Clinical Trials as Topic
  • Dipeptides / administration & dosage
  • Dipeptides / pharmacokinetics
  • Dipeptides / therapeutic use*
  • Drug Administration Schedule
  • Drug Evaluation, Preclinical
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Injections, Intramuscular
  • Lassa virus / drug effects
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / growth & development
  • Papillomaviridae / drug effects
  • Spleen / cytology
  • Spleen / drug effects
  • Thymus Gland / cytology
  • Thymus Gland / drug effects
  • Tuberculosis / drug therapy*

Substances

  • Adjuvants, Immunologic
  • Anti-Bacterial Agents
  • Antiviral Agents
  • Dipeptides
  • golotimod